SCHEMBL19735103

SCHEMBL19735103

CC(C)C1CN(C(=O)CN2CC(O)C2)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
RAB9A P51151 1/20 0.37
BIRC2 Q13490 1/20 0.35
GAA P10253 1/20 0.33
PIK3CD O00329 1/20 0.32
ALOX15 P16050 1/20 0.32
TSHR P16473 1/20 0.32
HSD17B10 Q99714 1/20 0.32
JAK2 O60674 1/20 0.31
JAK1 P23458 1/20 0.31
TYK2 P29597 1/20 0.31
JAK3 P52333 1/20 0.31
CHRNB2 P17787 2/20 0.31
CHRNA3 P32297 2/20 0.31
CHRNA4 P43681 2/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CHRNB3 Q05901 1/20 0.31
CHRNA6 Q15825 1/20 0.31
TLR9 Q9NR96 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24492123 0.82 GAA (0.55) KDM4ELMNARAB9ABIRC2GAA
SCHEMBL24023956 0.82 GAA (0.50) KDM4ELMNARAB9ABIRC2GAA
SCHEMBL19738914 0.79 KDM4E (0.47) KDM4ELMNARAB9ABIRC2GAA
SCHEMBL27051351 0.78 SIGMAR1 (0.40) KDM4ELMNARAB9ABIRC2GAA
SCHEMBL24023548 0.78 HSD17B10 (0.61) KDM4ELMNARAB9AGAAALOX15
SCHEMBL25075102 0.77 LMNA (0.43) KDM4ELMNARAB9ABIRC2GAA
SCHEMBL19735100 0.75 CHRNB2 (0.35) CHRNB2CHRNA3CHRNA4SMN1; SMN2CHRNB3
SCHEMBL24312689 0.75 PIK3CD (0.36) PIK3CDCHRNB2CHRNA3CHRNA4CHRNB3
SCHEMBL15247313 0.75 CHRNB2 (0.53) LMNACHRNB2CHRNA3CHRNA4SMN1; SMN2
SCHEMBL26494180 0.75 GAA (0.42) KDM4ELMNARAB9ABIRC2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10730880-B2 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-08-04 US disclosed
US-20170362240-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2017-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10730880-B2 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors JAK1, JAK3, JAK2 KDM4E 726/4885LMNA 4865/4885RAB9A 2771/4885
US-20170362240-A1 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS JAK1, JAK3, JAK2 KDM4E 726/4885LMNA 4865/4885RAB9A 2771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.